Multiple Sclerosis (MS) - Relapsing-remitting Clinical Trials

9 recruiting

Frequently Asked Questions

Common questions about Multiple Sclerosis (MS) - Relapsing-remitting clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 4

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

Multiple SclerosisMultiple Sclerosis (MS) - Relapsing-remitting
Northwestern University40 enrolled1 locationNCT07225361
Recruiting
Not Applicable

Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study

Multiple Sclerosis (MS) - Relapsing-remittingUpper Extremity Dysfunction
University of Florida15 enrolled2 locationsNCT07376772
Recruiting
Early Phase 1

Effects of Ublituximab on Motor Functions in Multiple Sclerosis

Multiple Sclerosis (MS) - Relapsing-remitting
Georgia State University25 enrolled2 locationsNCT06629428
Recruiting
Not Applicable

Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)

PARKINSON DISEASE (Disorder)Multiple Sclerosis (MS) - Relapsing-remittingPediatric Patients Affected by Neuromuscolar and Degenerative Diseases
IRCCS Centro Neurolesi Bonino Pulejo300 enrolled1 locationNCT07360977
Recruiting
Not Applicable

Home Based Functional Balance Intervention for Multiple Sclerosis

Multiple SclerosisMultiple Sclerosis (MS) - Relapsing-remittingMultiple Sclerosis (MS) Primary Progressive+2 more
University of Illinois at Chicago75 enrolled1 locationNCT07355387
Recruiting

"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS

Multiple SclerosisMS (Multiple Sclerosis)Multiple Sclerosis (MS) - Relapsing-remitting+3 more
University of California, San Francisco300 enrolled1 locationNCT07222618
Recruiting

Sexual Dysfunction in Women With Multiple Sclerosis (MS)

Sexual DisfunctionDepressionCognitive Dysfunction+6 more
Ege University140 enrolled1 locationNCT07193823
Recruiting
Not Applicable

Study to Investigate Vagus Nerve Stimulation Paired With Motor Task for Remyelination and Functional Recovery

Multiple SclerosisMultiple Sclerosis (MS) - Relapsing-remitting
University of Colorado, Denver70 enrolled1 locationNCT06641271
Recruiting

Deuterium Metabolic Imaging in People with Multiple Sclerosis

Multiple Sclerosis (MS) - Relapsing-remitting
University of Aarhus20 enrolled1 locationNCT06611280